Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H20N4O2 |
Molecular Weight | 264.3235 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O
InChI
InChIKey=MRWQRJMESRRJJB-UHFFFAOYSA-N
InChI=1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3
Molecular Formula | C13H20N4O2 |
Molecular Weight | 264.3235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pentifylline is an active vasodilating substance which does not affect blood sugar levels. Pentifylline inhibits the soluble and the particulate cyclic AMP phosphodiesterases from bovine platelets and rat brain ATPase. The inhibition of ATPase by pentifylline was not influenced by the change in Na+/K+ ratio. Pentifylline in combination with Nicotinic acid indicated for the treatment of Cerebral circulatory disorders and Circulatory disorders of the eye. Pentifylline is well tolerated but it is recommended that blood pressure be monitored and if there is a severe drop in blood pressure, a drip infusion of plasma expander be administered. Coagulation states should also be closely watched.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2097166 Sources: https://www.ncbi.nlm.nih.gov/pubmed/170944 |
2.0 mM [IC50] | ||
Target ID: CHEMBL3477 Sources: https://www.ncbi.nlm.nih.gov/pubmed/170944 |
0.81 mM [IC50] | ||
Target ID: Brain ATPase (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/227424 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COSALDON Approved UseIndicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye. |
|||
Primary | COSALDON Approved UseIndicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye. |
PubMed
Title | Date | PubMed |
---|---|---|
[Cerebral sclerosis and its treatment with cosaldon]. | 1957 Jun 14 |
|
[On the applicability of cosaldon in the treatment of cerebral sclerotic parkinsonism]. | 1959 Aug 7 |
|
[Some aspects of the pharmacological activity of a new theophylline: 1-hexyl-3, 7-dimethylxanthine (SK-7)]. | 1960 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/hmr/cosaldrt.html
Cerebral and peripheral circulatory disorders: 400 mg one tablet twice daily (Initial and normal dose) or 400 mg tablet daily for as long as necessary (Maintenance dose).
Circulatory disorders of the eye: 400 mg two or three times daily (Initial and normal dose) or 400 mg once or twice daily for as long as necessary (Maintenance dose).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8829173
The secretion of type-I collagen COOH-terminal peptide (PIP) into the culture medium in the presence of pentifylline (PTF) was significantly lower than that in the presence of pentoxifylline (PTX) at concentrations of 10-1000 ug/ml; its level in cell lysate in the presence of PTX at concentrations of 10-100 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:51:07 GMT 2023
by
admin
on
Sat Dec 16 17:51:07 GMT 2023
|
Record UNII |
MBM1C4K26S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
||
|
WHO-ATC |
C04AD01
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
||
|
WHO-VATC |
QC04AD01
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m8510
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID2057609
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
DB13634
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
100000082514
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
SUB09694MIG
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
2094
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
3310
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
70569
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
PENTIFYLLINE
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
33086
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | RxNorm | ||
|
MBM1C4K26S
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105338
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
C66344
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
C007942
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
213-842-0
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY | |||
|
1028-33-7
Created by
admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |